Skip to main content

Robotic Platforms & Manufacturers

The da Vinci system (Intuitive Surgical) has defined robotic urologic surgery since 2000, but the market is now genuinely multi-vendor. At least eleven clinical or late-stage robotic platforms are in use or imminent launch globally, with meaningful differences in console architecture, instrument design, haptic feedback, and cost.[1][2][3][4] This page catalogs the manufacturers, platforms, and the features that matter when choosing — or reading an outcomes paper from — one.

See also: Reconstructive Applications, Single-Port Robotics.

Platform Overview​

PlatformManufacturerHQStatusConsoleKey Feature
da Vinci Si / Xi / XIntuitive SurgicalSunnyvale, CA, USAFDA + CEClosed, immersiveMarket reference standard
da Vinci SPIntuitive SurgicalSunnyvale, CA, USAFDA 2018, CE 2024ClosedSingle-port, flexible camera + articulating instruments
da Vinci 5Intuitive SurgicalSunnyvale, CA, USAFDA 2024ClosedForce feedback ("Force Feedback" instruments), improved 3D
Hugo RASMedtronicMinneapolis, MN, USACE 2021, FDA pending (IDE)Open, 3DModular arm carts — table-independent docking
VersiusCMR SurgicalCambridge, UKCE 2019, FDA 2025Open, 3D, seatedPortable per-arm bedside units; wristed 5 mm instruments
SenhanceAsensus Surgical (prev. TransEnterix)Morrisville, NC, USAFDA 2017, CE 2012Open with eye-trackingHaptic force feedback + eye-tracking camera control
AvateraAvateramedicalJena, GermanyCE 2019Closed5 mm instruments with 6 DOF; disposable sterile instruments
HinotoriMedicaroid (Kawasaki + Sysmex JV)Kobe, JapanPMDA 2020, limited CE/FDAOpen, 3D8-axis arm geometry; Japanese domestic leader
REVO-I (MSR-5000)Meere CompanyYongin, South KoreaKFDA 2017ClosedFirst Korean platform; low acquisition cost target
KangDuoSuzhou Kangduo Robot Co.Suzhou, ChinaNMPA 2022ClosedUsed in multi-center Chinese trials for prostatectomy and partial nephrectomy
MicroHand STianjin Weigao / Tianjin UniversityTianjin, ChinaNMPA 2018ClosedFirst Chinese master-slave surgical robot
ToumaiMicroPort MedBotShanghai, ChinaNMPA 2022ClosedUsed for telesurgery (Beijing–Xinjiang 2022 demonstration)
DexterDistalmotionLausanne, SwitzerlandCE 2022OpenSeat-and-stand hybrid; drop-in laparoscopic instruments + robotic arms
Telelap ALF-XSOFAR → TransEnterix (now Senhance lineage)Milan, ItalyHistorical / evolved into SenhanceOpenOriginal eye-tracking + haptic design — progenitor of Senhance

Intuitive Surgical — da Vinci​

Intuitive Surgical (Sunnyvale, CA) has dominated robotic surgery since the 2000 FDA clearance of the original da Vinci. The product family matters because outcomes literature spans multiple generations:

  • da Vinci Si (2009) — dual-console, HD 3D, legacy workhorse still in wide use internationally.
  • da Vinci Xi (2014) — overhead boom, thinner arms, 360° arm rotation, easier multi-quadrant docking. The dominant platform in US urology from 2015 to 2024.
  • da Vinci X (2017) — cost-reduced Xi variant (Si-era arms on Xi boom) for emerging markets.
  • da Vinci SP (2018, FDA; 2024, CE) — single-port system; 2.5 cm cannula houses a flexible 3D endoscope + three multi-jointed wristed instruments. See Single-Port Robotics.[5][6]
  • da Vinci 5 (2024) — 10,000× the computing power of Xi; Force Feedback instruments provide proprioceptive tension data to the surgeon (the first shipped haptic capability on a da Vinci multi-port system); improved 3D imaging and case-insights data.

Instrument ecosystem: 8 mm wristed EndoWrist instruments (multi-port platforms); 6 mm articulating instruments on SP; disposable / use-limited instruments drive per-case consumable cost.

Medtronic — Hugo RAS​

Medtronic's Hugo RAS system (Minneapolis, MN) is the principal Intuitive competitor in Western markets. CE-marked 2021; FDA IDE trials in US urology ongoing.

  • Modular architecture: four independent arm carts can be positioned around the table rather than a single fixed cart — useful for multi-quadrant cases and low-volume sites where the cart footprint must be stored between cases.
  • Open console with 3D HD visualization — surgeon retains situational awareness of the OR.
  • Integrated Touch Surgery digital platform — video capture, analytics, remote case review.
  • Clinical urology data emerging from Europe and India (RAPN, RARP, cystectomy feasibility series).

CMR Surgical — Versius​

Versius (Cambridge, UK) targets small and mid-size hospitals with a portable, arm-by-arm modular system. CE-marked 2019; FDA cleared 2025 for soft-tissue surgery.

  • Each arm is wheeled to the tableside independently — the system is smaller and cheaper to ship/install than da Vinci or Hugo.
  • Seated, open console with 3D HD visualization.
  • 5 mm wristed instruments — 7 DOF.
  • Wide cholecystectomy, colorectal, and gynecology deployment globally; urologic adoption building.

Asensus Surgical — Senhance​

Senhance (Morrisville, NC; formerly TransEnterix) is the only commercially available platform offering true haptic (force) feedback and eye-tracking camera control — inherited from the Telelap ALF-X progenitor.[1][2]

  • Surgeon feels tissue tension at the instrument tip — meaningful for microsurgery and reconstructive anastomosis work.
  • Eye-tracker moves the camera based on gaze, freeing a hand.
  • Uses reusable laparoscopic instruments (low per-case consumable cost).
  • "Intelligent Surgical Unit" (ISU) — FDA-cleared machine-vision augmentation layer (digital tagging, scene awareness).

Avateramedical — Avatera​

Avatera (Jena, Germany; CE 2019) targets a different niche: 5 mm wristed instruments with 6 degrees of freedom and fully sterile disposable instrument sets to eliminate reprocessing.

  • Closed, immersive console.
  • Smaller port footprint than 8 mm da Vinci instruments — theoretical cosmesis and pain advantages.
  • Primarily European deployment to date.

Medicaroid — Hinotori​

Hinotori (Kobe, Japan; PMDA 2020) is a Kawasaki Heavy Industries / Sysmex joint venture — Japan's domestic robot of choice.

  • Open 3D console, 8-axis arm geometry for flexible docking.
  • Japanese urology series reporting comparable outcomes to da Vinci in RARP.

Meere Company — REVO-I​

REVO-I (MSR-5000; Yongin, South Korea; KFDA 2017) is the first Korean robotic platform with clinical urology data.

  • Closed immersive console with 3D.
  • Lower acquisition cost is an explicit design goal.
  • Early RARP series from Korean centers with feasibility data.

Chinese Platforms — KangDuo, MicroHand S, Toumai​

Three Chinese platforms have NMPA approval and a growing clinical footprint:

  • MicroHand S (Tianjin Weigao / Tianjin University; NMPA 2018) — first Chinese master-slave robot, used across general and urologic surgery.
  • KangDuo (Suzhou Kangduo Robot Co.; NMPA 2022) — multi-center Chinese trials for prostatectomy, partial nephrectomy, and pyeloplasty.
  • Toumai (MicroPort MedBot, Shanghai; NMPA 2022) — notable for a 2022 telesurgery demonstration across ~5,000 km (Beijing to Xinjiang), foreshadowing distance-surgery applications.

Distalmotion — Dexter​

Dexter (Lausanne, Switzerland; CE 2022) is a hybrid laparoscopic-robotic system.

  • Surgeon alternates between standing at the bedside with conventional laparoscopic instruments and sitting at an open console controlling two robotic arms plus a robotic camera.
  • Lower capital cost than da Vinci; designed for laparoscopic-trained surgeons transitioning to robotic work.
  • Growing European urologic adoption.

Feature Axes That Matter​

When reading comparative papers or evaluating a platform for institutional purchase, these are the axes along which they actually differ:

  • Console design: closed/immersive (da Vinci, Avatera, REVO-I) vs open/3D (Hugo, Versius, Senhance, Hinotori, Dexter). Open consoles preserve OR awareness; closed consoles maximize surgeon immersion.
  • Haptic feedback: Senhance is the only multi-port system with true force feedback in production; da Vinci 5 adds partial force-feedback instruments (2024); Telelap ALF-X lineage originated the capability.
  • Eye-tracking camera control: Senhance (inherited from Telelap ALF-X).
  • Modular architecture: Hugo (cart-per-arm) and Versius (unit-per-arm) — table- and room-flexibility; da Vinci remains boom-based.
  • Instrument size: Avatera (5 mm, 6 DOF) and Versius (5 mm, 7 DOF) at the smaller end; da Vinci Xi at 8 mm; SP at 6 mm articulating.
  • Cost: acquisition for da Vinci Xi ~$2M USD + annual service + per-case consumables is the benchmark; Hugo, Versius, Dexter, Hinotori, REVO-I, and the Chinese platforms compete primarily on price and consumable model.[1][4]
  • Instrument reuse model: reusable (Senhance, Versius partial) vs use-limited / disposable (da Vinci, Avatera) — drives per-case economics.

Future Directions​

Incremental platform features are converging on a short list of anticipated developments:[1][4][7]

  • Force-feedback / true haptics on every platform — da Vinci 5 is the first multi-port da Vinci with it; expect this to become table stakes.
  • Integrated AI / computer-vision augmentation — anatomic segmentation, autonomous suturing modules, scene-safety alerts.
  • Augmented-reality overlay — registered preoperative imaging onto the live surgical field (useful for partial nephrectomy, nerve-sparing RP).
  • Telesurgery — the Toumai Beijing–Xinjiang case demonstrated the technical feasibility; latency, regulatory, and malpractice frameworks are the gating factors.
  • Miniaturization — 3–5 mm instrument platforms, reduction to bedside-unit form factors.
  • Autonomous / semi-autonomous task modules — knot-tying, pattern suturing, instrument exchange.

References​

1. Katsimperis S, Tzelves L, Feretzakis G, et al. "Beyond Da Vinci: Comparative Review of Next-Generation Robotic Platforms in Urologic Surgery." J Clin Med. 2025;14(19):6775. doi:10.3390/jcm14196775

2. Farinha R, Puliatti S, Mazzone E, et al. "Potential Contenders for the Leadership in Robotic Surgery." J Endourol. 2022;36(3):317–326. doi:10.1089/end.2021.0321

3. Kallidonis P, Gkeka K, Tatanis V, et al. "Novel Robotic Platforms for Robot-Assisted Laparoscopic Surgery in Urology: A Narrative Review." J Endourol. 2024;38(7):652–660. doi:10.1089/end.2023.0732

4. Alip SL, Kim J, Rha KH, Han WK. "Future Platforms of Robotic Surgery." Urol Clin North Am. 2022;49(1):23–38. doi:10.1016/j.ucl.2021.07.008

5. Biasatti A, Soputro NA, Porpiglia F, et al. "The Current Landscape of Single-Port Robotic Surgery in Urology." Nat Rev Urol. 2026;23(3):156–173. doi:10.1038/s41585-025-01081-z

6. Dobbs RW, Halgrimson WR, Talamini S, et al. "Single-Port Robotic Surgery: The Next Generation of Minimally Invasive Urology." World J Urol. 2020;38(4):897–905. doi:10.1007/s00345-019-02898-1

7. Rassweiler JJ, Autorino R, Klein J, et al. "Future of Robotic Surgery in Urology." BJU Int. 2017;120(6):822–841. doi:10.1111/bju.13851